These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35874658)

  • 1. PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report.
    Xu H; Hong Z; Xu M; Kong Y; Ma Y; Shan C; Xing P; Zhang L
    Front Immunol; 2022; 13():926740. PubMed ID: 35874658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report.
    Liu Z; Wang F; Zhang Y; Lu J; Yang Y
    Front Immunol; 2024; 15():1321946. PubMed ID: 38361930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study.
    Kong Y; Zhao X; Xu M; Pan J; Ma Y; Zou L; Peng Q; Zhang J; Su C; Xu Z; Zhou W; Peng Y; Yang J; Zhou C; Li Y; Guo Q; Chen G; Wu H; Xing P; Zhang L
    Front Immunol; 2022; 13():952066. PubMed ID: 35874780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report.
    Yang J; Xing P; Kong Y; Xu M; Zhang L
    Front Oncol; 2023; 13():1078915. PubMed ID: 37188188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance.
    Chen KH; Yuan CT; Tseng LH; Shun CT; Yeh KH
    J Hematol Oncol; 2016 Mar; 9():29. PubMed ID: 27012666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer.
    Hwang JE; Kim HN; Kim DE; Choi HJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Cho SH; Chung IJ
    BMC Cancer; 2011 Nov; 11():489. PubMed ID: 22103888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy.
    Zhao F; Li E; Shen G; Dong Q; Ren D; Wang M; Zhao Y; Liu Z; Ma J; Xie Q; Liu Z; Li Z; Gao L; Zhao J
    J Gastroenterol; 2023 Jul; 58(7):622-632. PubMed ID: 37036516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Kang YK; Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Chen LT
    Lancet; 2017 Dec; 390(10111):2461-2471. PubMed ID: 28993052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma.
    Partyka S; Dumas P; Ajani J
    Cancer; 1999 Jun; 85(11):2336-9. PubMed ID: 10357402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer.
    Qin Y; Huang S; Tang J; Fan Y; Deng X; Guan P; Zhang Z; Wen Q; Li D
    Front Immunol; 2023; 14():1329951. PubMed ID: 38235148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
    Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
    J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
    Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
    Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-day DCF regimen in patients with metastatic gastric cancer.
    Dirican A; Kucukzeybek Y; Tarhan MO; Somali I; Erten C; Demir L; Can A; Bayoglu IV; Akyol M; Ekinci N; Medeni M; Koyuncu B; Alacacioglu A
    Tumori; 2013; 99(2):145-8. PubMed ID: 23748805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
    Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Fuchs CS; Shitara K; Di Bartolomeo M; Lonardi S; Al-Batran SE; Van Cutsem E; Ilson DH; Alsina M; Chau I; Lacy J; Ducreux M; Mendez GA; Alavez AM; Takahari D; Mansoor W; Enzinger PC; Gorbounova V; Wainberg ZA; Hegewisch-Becker S; Ferry D; Lin J; Carlesi R; Das M; Shah MA;
    Lancet Oncol; 2019 Mar; 20(3):420-435. PubMed ID: 30718072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study.
    Zhao L; Fu Y; Niu P; Zhang F; Jiao F; Zhou X; Wu Z; Wang W; Luan X; Han X; He M; Guan Q; Li Y; Zhao D; Gao J; Chen Y
    Oncologist; 2023 Oct; 28(10):e891-e901. PubMed ID: 37104872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study.
    Bajetta E; Di Bartolomeo M; Carnaghi C; Buzzoni R; Mariani L; Gebbia V; Comella G; Pinotti G; Ianniello G; Schieppati G; Bochicchio AM; Maiorino L
    Br J Cancer; 1998 Apr; 77(7):1149-54. PubMed ID: 9569054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
    Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
    Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade.
    Randon G; Aoki Y; Cohen R; Provenzano L; Nasca V; Klempner SJ; Maron SB; Cerantola R; Chao J; Fornaro L; Ferrari Bravo W; Ghelardi F; Ambrosini M; Manca P; Salati M; Kawazoe A; Zhu V; Cowzer D; Genovesi V; Lonardi S; Shitara K; André T; Pietrantonio F
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37277193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.